Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

This study is testing an experimental drug called NEROFE — a novel hormone-like peptide — in adults with advanced blood cancers: acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). These are cancers of the bone marrow that affect blood cell production. NEROFE works through a different mechanism than most existing cancer drugs and may offer hope when other treatments have failed. **You may be eligible if:** - You have relapsed or treatment-resistant AML or MDS — meaning your cancer came back or never responded to standard therapies - For AML: no alternative life-prolonging treatments are available, or you have high-risk disease unlikely to respond to other options - For MDS: your disease did not achieve complete remission or has progressed on or after standard treatments - You are in a condition that allows you to receive the study drug **You may NOT be eligible if:** - Your cancer is well-controlled or responding to current treatment - You have other serious conditions that would make participation unsafe - You do not meet the specific diagnostic and treatment history requirements Talk to your doctor to see if this trial is right for you.